Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE
A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince another fleet of new and returning investors to back their upstart approach for a rare genetic condition called hereditary angioedema, or HAE.
The company said Wednesday that they’ve raised an $80 million Series C led by Viking Global Investors and General Atlantic. They’ll plow that cash directly into a pair of Phase II trials to test whether their lead molecule can become the first oral drug to successfully treat and prevent the painful episodes HAE triggers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.